ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Lists
Only you see this
BibTeX
@article{motzer2019entrata,
author = {Robert J. Motzer and Chung‐Han Lee and Hamid Emamekhoo and Marc Matrana and Ivor Percent and James J. Hsieh and Arif Hussain and Ulka N. Vaishampayan and R Graham and S. Liu and Steve McCune and Montaser Shaheen and Hema Parmar and Yuning Shen and Sam H. Whiting and Nizar M. Tannir},
title = {{ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)}},
journal = {Annals},
year = {2019},
doi = {10.1093/annonc/mdz394.048},
}Loading related content...